Classification of the four main types of lung cancer using a microRNA-based diagnostic assay.
暂无分享,去创建一个
Ranit Aharonov | Iris Barshack | Marluce Bibbo | Tina Bocker Edmonston | R. Aharonov | M. Bibbo | S. Gilad | M. Feinmesser | I. Barshack | J. Hou | N. Dromi | T. Edmonston | I. Burnstein | B. St Cyr | S. Benjamin | Gila Lithwick-Yanai | Shlomit Gilad | Hadas Gibori | Gila Lithwick-Yanai | Yajue Huang | Sima Benjamin | Irit Krivitsky | Craig Thurm | Laurie Horowitz | Yajue Huang | Meora Feinmesser | J Steve Hou | Brianna St Cyr | Ilanit Burnstein | Nir Dromi | Mats Sanden | Michal Kushnir | H. Gibori | M. Kushnir | C. Thurm | L. Horowitz | Mats O. Sanden | I.Yu. Krivitsky | G. Lithwick-Yanai | Iris Barshack | B. S. Cyr | Ilanit Burnstein
[1] K. Jöckel,et al. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. , 2006, Lung cancer.
[2] A R Feinstein,et al. Observer Variability in the Histopathologic Diagnosis of Lung Cancer1, 2 , 2015 .
[3] R. A. Robinson,et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.
[4] L. Seymour,et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. , 2006, Clinical lung cancer.
[5] R. Tonelli,et al. Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives. , 2011, Journal of proteomics.
[6] T. Ha. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease , 2011, Immune network.
[7] H. Benjamin,et al. Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach , 2010, Clinical Cancer Research.
[8] R. Herbst,et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Gideon Rechavi,et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Y. Yatabe,et al. Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .
[12] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[13] Q. K. Li,et al. Cytologic diagnosis and differential diagnosis of lung carcinoid tumors a retrospective study of 63 cases with histologic correlation , 2010, Cancer cytopathology.
[14] A. Schetter,et al. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.
[15] Stijn van Dongen,et al. miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..
[16] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] Yariv Yogev,et al. Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.
[18] Iris Barshack,et al. MiR‐92b and miR‐9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors , 2008, Brain pathology.
[19] C. Morrison,et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.
[20] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[21] Thomas Tuschl,et al. miRNAs in human cancer , 2011, The Journal of pathology.
[22] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[23] John S Mattick,et al. Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7* , 2009, Journal of Biological Chemistry.
[24] A. Sandler. Bevacizumab in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[25] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Guanghai Yang,et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). , 2010, Clinica chimica acta; international journal of clinical chemistry.
[27] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[28] R. Aharonov,et al. MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.
[29] E. Wang,et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells , 2010, BMC Cancer.
[30] A. Schetter,et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.
[31] Bo Jian,et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.
[32] H. Asamura,et al. Immunohistochemical expression of TTF‐1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity , 2007, Pathology international.
[33] Shu Zheng,et al. Epidermal growth factor receptor-regulated miR-125a-5p – a metastatic inhibitor of lung cancer , 2009, The FEBS journal.
[34] D. Burstein,et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.
[35] Avrum Spira,et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. , 2010, Cell cycle.
[36] Anne-Marie C. Dingemans,et al. MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer , 2011, PloS one.
[37] C. Gomez-Fernandez,et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples , 2009, Cancer.